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Working rat hearts perfused with 5.5 mM glucose were submitted to a IO-min period of no-flow ischaemia or anoxia. Both conditions stimulated 
glycogenolysis, activated phosphorylase. and increased cyclic GMP content, although the time course of these changes differed in anoxia and 
ischaemia. Changes in cyclic GMP content were not correlated with glycogenolysis or phosphorylase activation. Perfusion with 1 PM L-nitroarginine 
methylester, an inhibitor of nitric oxide synthase, decreased cGMP concentration under normoxic conditions and abolished the ischaemia-induced 
increase in cGMP. The inhibitor decreased the coronary flow without affecting the overall working performance of the hearts under normoxic 
conditions. 
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1. Iutrodaction 
Under normal conditions, the energy consumed by the 
heart is provided by the oxidation of substrates that are 
taken up from the circulation, so that the endogenous 
stores of triglycerides and glycogen are not used for en- 
ergy production [l-3]. In contrast, glycogen becomes a 
predominant source of energy during ischaemia or hy- 
poxia when myocardium shifts to anaerobic glycolysis 
for its energy supply [2,3]. This shift, the well-known 
‘Pasteur effect’, results from changes in the concentra- 
tion of metabolic regulators such as adenine nucleotides 
and inorganic phosphate that act at the level of glycogen 
phosphorylase and 6-phosphofructo-1-kinase, a key en- 
zyme of glycolysis [4,5]. Second messengers such as cyclic 
AMP (CAMP), inositol 1,4,5-t&phosphate (IP,), and 
calcium may play a role in this short-term metabolic 
adaptation. For instance, the effects of CAMP or calcium 
on glycogen breakdown and glycogen phosphorylase ac- 
tivation have been studied in hypoxic myocardium [6-S]. 
To the best of our knowledge, nothing is known about 
changes in the content of cardiac cyclic GMP (cGMP) 
during ischaemia. If present, such modifications could 
have significant physiological and metabolic conse- 
*Corresponding author. Fax: (32) (2) 762 7455. 
Emaik hue@ucl.ac.be. 
Abbreviations: ATP, adenosine triphosphate; CAMP, 3’,5’-cyclic ade- 
nosine monophosphate; cGMP, 3’,5’-cyclic guanosine monophosphate; 
Fru-1,6-P,, fructose 1,dbisphosphate; Fru-2,6-P,, fructose 2,6-bis- 
phosphate; IP,, inositol trisphosphate. 
quences, because cGMP is known to regulate CAMP 
phosphodiesterase [9,10]. cGMP could also control, via 
the cGMP dependent protein kinase, the intracellular 
calcium concentration and the phosphorylation state of 
several proteins [9,11,12]. 
In this work, we studied the variations in CAMP, 
cGMP, and IP3 concentration in rat hearts submitted to 
ischaemia or anoxia, and we compared these variations 
to the time course of glycogen breakdown and the accu- 
mulation of glycolytic intermediates. 
2. Experimental 
2.1. Perfusion protocol 
Hearts from male Wistar fed rats (18&250 g) were perfused under 
‘working’ conditions [13,14] with a preload of 10 cm water and an 
afterload of 90 cm water. The hearts were perfused at 37T with a 
Krebs-Henseleit buffer containing 5.5 mM glucose as the sole sub- 
strate, and in equilibrium with a 95% 045% CO,gas phase. After 15 
min of perfusion, the hearts were submitted to either a global no-flow 
ischaemia, by clamping the perfusate supply to the hearts, or a period 
of anoxia, by perfusing the same medium in equilibrium with 95% 
N,/5% COgas phase. The hearts were freezeclamped at the times 
indicated. Heart rate and aortic pressure were continuously monitored 
on a Gould recorder via a Statham transducer connected to a side-arm 
of the aortic cammla. Aortic and coronary outputs were measured with 
a graduated glass cylinder. The work produced by the heart was calcu- 
lated from the product of the cardiac output (in kilograms) and the 
afterload (in meters) and was expressed by unit of time as the hydraulic 
power (kg.mmin-i) [I 31. 
2.2. Analytical procedures 
ATP [15], hexose 6-phosphates (i.e. the sum of glucose 6-phosphate 
and fructose dphosphate) [16] and fructose 1,6-bisphosphate @u-1,6- 
P;) [l fl were measured enxymatically in neutralized perchloric acid 
extracts. Fructose 2,dbisphosphate (Fru-2,6-P& was measured in alka- 
line extracts [18]. Glycogen content was measured enxymatically in an 
alkaline extract and expressed as glucose equivalents [19]. CAMP, 
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cGMP and IP, were measured by immunoassays with the correpondmg 
assay kits purchased from Amersham, UK. Glucose phosphorylation 
and glycolysis were evaluated by the rate of detritiation of [2-‘H]- and 
[3-‘H&lucose, respectively [20,21]. The active form of glycogen 
phosphorylase (phosphorylase a) was measured at 25°C as described 
[19]. One unit of enzyme activity corresponds to the formation of 
1 pmol of product per mm under the assay conditions. 
2.3. Statistical analysis 
All the values are means + S.E.M. for the number of different prep- 
arations given in the legends, and are expressed per g of dry weight 
(g.d.w.). Unpaired two-tailed Student’s t-test was used to determine 
statistically significant (P < 0.05) differences between groups. 
3. Results 
3.1. Comparison of anoxia and ischaemia 
A comparison was first made of the effects of is- 
chaemia and anoxia on glycogen breakdown (Fig. lA), 
glycogen phosphorylase activation (Fig. 1B) and cyclic 
nucleotides concentration (Fig. 2). Both ischaemia and 
anoxia stimulated glycogen breakdown with an average 
rate of about 6 ~mol+min-leg-‘d.w. The rate of glyco- 
genolysis was faster during the first 5 min of anoxia than 
during the corresponding period of ischaemia. Accord- 
ingly, glycogen phosphorylase was activated more rap- 
idly in anoxia than in ischaemia (Fig. 1B). However, this 
activation was transient in anoxia, whereas it was slower 
and persisted during the 10 min period of ischaemia. 
CAMP increased within 1 min of ischaemia (Fig. 2A). 
This increase was transient and CAMP returned to con- 
trol values within 2 min, suggesting that the maximal 
activation of phosphorylase reached at 4 min of is- 
chaemia and onwards (Fig. 1B) cannot be attributed to 
a CAMP-dependent mechanism. In anoxia, no significant 
changes in the concentration of CAMP could be detected 
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(Fig. 2B). Therefore, and in general agreement with pre- 
vious report [22], phosphorylase activation does not 
seem to be dependent on CAMP in anoxia as in is- 
chaemia. Messengers other than CAMP should thus be 
involved for the activation of phosphorylase, and, as 
already suggested [23], Ca2’ is a possible candidate. IP, 
is probably not involved in Ca” mobilization under 
these conditions, because its concentration was 
4.2 f 0.05 pmoYg under normoxic conditions and re- 
mained unaltered during ischaemia. 
The changes in cGMP content were also measured and 
Fig. 2A shows that cGMP increased within 1 min of 
ischaemia and remained elevated during the 10 min pe- 
riod of ischaemia. In anoxia, no significant change in the 
concentration of cGMP could be detected at 2 and 4 min, 
and the concentration of cGMP became elevated only 
towards the end of the anoxic period (Fig. 2B). 
The concentration of some glycolytic intermediates 
was also compared in ischaemic and anoxic hearts (Table 
1). The concentration of hexose 6-phosphates increased 
almost 3-fold during ischaemia, whereas it slightly de- 
creased during anoxia, with the lowest values found at 
5 min. The concentration of Fru-1,6-P, increased uring 
both ischaemia and anoxia; however, the changes were 
larger in anoxia than in ischaemia. In agreement with 
previous work [14], the concentration of Fru-2,6-P,, a 
regulator of heart glycolysis under aerobic conditions, 
was not different in ischaemic and anoxic hearts (average 
value: 14 + 2 muol/g.d.w.) and did not differ from the 
values found in normoxic hearts, thus ruling out Fru-2,6- 
P, as a key element in the stimulation of heart glycolysis 
during ischaemia and anoxia. No difference between is- 
chaemia and anoxia was found in the fall of ATP concen- 
trations. 
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Fig. 1. Time course of glycogen breakdown (A) and phosphorylase activation (B) in rat hearts submitted to ischaemia or anoxia. The hearts were 
perfused for 15 min under normoxic conditions before ischaemia or anoxia. They were freexe-clamped after the indicated periods of ischaemia or 
anoxia. The values are means f S.E.M. for at least five different preparations. *Statistically sign&ant difference between ischaemia nd anoxia at 
the same time point. 
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Fig. 2. Time course of the changes in CAMP and cGMP concentration in rat hearts submitted to ischaemia (A) or anoxia (B). The hearts were perfused 
for 15 min under normoxic conditions before ischaemia or anoxia. The hearts were freeze-clamped after the indicated periods of ischaemia or anoxia. 
CAMP (open circles) and cGMP (open squares, control hearts; tilled squares, hearts with L-NAME) contents were measured. Some hearts were 
perfused for 5 min before ischaemia with 1 PM L-NAME. The values are means f S.E.M. for at least five different preparations. *Statistically 
significant different from the corresponding value at 0 min. #Statistically sign&ant different from the corresponding values without L-NAME. 
3.2. Effects of L-nitroarginine methylester in ischaemia 
and normoxia 
without effect on the concentration of cyclic AMP (aver- 
age value: 2.1 + 0.2 nmol/g.d.w.) 
Nitric oxide (NO) is known to increase the concentra- Since NO is known to affect vascular resistance [24], 
tion of cGMP in certain tissues [24]. Therefore, we inves- it was important to check whether the function and me- 
tigated whether the ischaemia-induced increase in cGMP tabolism of normoxic hearts, as well as the metabolic 
content could be abolished by inhibition of NO synthase. response to ischaemia were affected by L-NAME. Table 
Hearts were perfused with 1 ,uM L-nitroarginine meth- 2 shows that, under normoxic condition, L-NAME was 
ylester (L-NAME), a specific inhibitor of NO synthase without effect on all the functional parameters tudied 
[25], which was added to the perfusion medium 5 mm (peak aortic pressure, heart rate, aortic flow, hydraulic 
before the onset of ischaemia. Fig. 2A shows that the power), except for the coronary flow, which was signifi- 
inhibitor not only decreased the normoxic values of cantly decreased. This is consistent with the known vas- 
cGMP content but also that it completely prevented the oconstrictive effect of inhibitors of the endothelial NO 
ischaemia-induced increase in cGMP L-NAME was synthase [26]. This also shows that the hearts perfused 
Table 1 
Concentration of hexose 6_phosphates, fructose l,dbisphosphate, ATP and glycogen in hearts submitted to ischemia or anoxia 
Conditions Duration Hexose-6-P Fru-1,6-P* ATP Glycogen 
Ischaemia 0 1.05 f 0.07 0.19 f 0.02 18f2 83 + 5 
5 2.73 z!z 0.20* 0.25 + 0.02 14 f 1* 50 + 5* 
10 2.75 f 0.15* 0.23 + 0.03 8 + 0.5* 20 + 4+ 
Ischaemia with L-NAME 0 1.40 f 0.20 0.06 + 0.01’ 18k2 78 + 4 
5 2.65 k 0.25* 0.11 r 0.02” 13*2* 58 + 3* 
10 2.80 f 0.20* 0.18 f O.Ol* 10 f 1* 30 + 4* 
Anoxia 0 1.13 f 0.10 0.21 k 0.03 20 + 2 77 + 7 
5 0.60 + 0.07* 0.33 zb 0.04*** 12 f 1* 43 f 2’ 
10 0.93 * 0.10* 0.40 f 0.33**# 10f 1 20f 1* 
The hearts were perfused for 15 min in normoxic conditions before ischaemia or anoxia. They were freeze-clamped after the indicated periods of 
ischaemia or anoxia. Some hearts were perfused for 5 min before ischaemia with 1 PM L-NAME. The values are means k S.E.M. for at least 6 different 
preparations. *P c 0.05, versus 0 min, same treatment; ‘P < 0.05, versus ischaemia lone at the same time. 
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Table 2 
Effects of L-NAME on the function and the metabolism of glucose in 
the normoxic working rat heart 
Controls L-NAME 
Peak systolic pressure (cm H,O) 100 f 10 105 f: 10 
Heart rate (beat/mm) 280 f 25 300 +15 
Aortic flow (ml/mm per g) 145 & 7 160 f 13 
Coronary flow (ml/mitt per g) 80 f7 60 * 5* 
Hydraulic power 
(kg.m/min per g) 0.202 f 0.015 0.198 f. 0.020 
[2-3H]Glucose detritiated 
@mol/min per g) 7.8 zb 0.8 8.0 f 0.6 
[3-3H]Glucose detritiated 
@mol/min per g) 7.2 + 0.8 7.9 f 0.5 
Lactate release 
Ormohmin per g) 8.0 f 0.8 8.0 f 0.9 
The hearts were perfused for 15 min in normoxic conditions with or 
without 1 PM L-NAME. The values are means f S.E.M. for at least 6 
different preparations. *P < 0.05 versus control. 
with L-NAME displayed a better ‘working’ efficiency, 
because the same hydraulic power was performed despite 
a decreased coronary flow. 
Glucose phosphorylation and glycolysis, as measured 
by the rate of detritiation of [2-3H]- and [3-3H]glucose, 
respectively, were not significantly affected by perfusion 
with L-NAME. The addition of L-NAME 5 min before 
ischaemia seemed to slower the ischaemia-induced glyco- 
genolysis (Table 1) although the difference was not statis- 
tically significant. Similarly the activation of phosphory- 
lase was not significantly affected by L-NAME (not 
shown). However, in the treated group, the concentra- 
tion of Fru-1,6-P,was lower than in the control group 
under both normoxic and ischaemic conditions (Table 
1). Moreover, the concentration of hexose 6-phosphates 
under normoxic conditions tended to be slightly larger 
in the presence of L-NAME than in the controls (Table 
1). 
L-NAME is not only an inhibitor of NO synthase but 
has also recently been reported to antagonize muscarinic 
receptors [27J. Therefore, we tested N-nitro-L-arginine, a 
more specific inhibitor of NO synthase without anti- 
cholinergic effects and we compared its effects with those 
of L-NAME. Table 3 shows that, under normoxic condi- 
tions, L-NAME and N-nitro+arginine decreased cGMP 
content and the coronary flow to the same extent. How- 
ever, the addition of 10m3 M L-arginine on top of 10e6 M 
L-NAME could prevent the fall in both cGMP concen- 
tration and coronary flow that were caused by L-NAME 
alone. These results indicate that, in our model, L- 
NAME is indeed acting as an inhibitor of NO synthase. 
4. Discussion 
4.1. Increase in cGA4P during ischaemia and anoxia 
This work is the first report of an ischaemia- or an- 
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oxia-induced increase in cGMP content in hearts. As to 
the mechanism responsible for this increase in cGMP 
content, the inhibitory effect of L-NAME, a known spe- 
cific inhibitor of NO synthase, suggests that heart cGMP 
concentration is controlled, at least in part, by NO. In- 
deed, the ischaemic-induced increase in cGMP was com- 
pletely prevented by the inhibitor. However, the basal 
cGMP content was only partly decreased by the inhibi- 
tor, and other substances, such as the auricular natriu- 
retie peptide (ANP), are known to influence the concen- 
tration of cGMP in heart. The mechanism by which NO 
synthase is activated in ischaemia remains to be eluci- 
dated. One possibility is the alteration of the intracellular 
Ca*’ content during ischaemia. Indeed, it has been dem- 
onstrated that the constitutive NO synthase can be acti- 
vated by Ca*+-dependent mechanism in certain tissues 
[28]. Although the presence of inducible and constitutive 
NO synthase has been documented for the heart, little is 
known about the control of the activity of the constitu- 
tive enzyme in this tissue. 
4.2. Control of glycolysis by ischaemia, anoxia and 
L-NAME 
Both ischaemia and anoxia are known to stimulate 
glycolysis [29]. The regulation is exerted mainly at the 
level of 6-phosphofructo-1-kinase and glucose transport 
[29]. However, as previously described [29,30], the 
changes in the concentrations of glycolytic intermediates 
observed during ischaemia and anoxia differed and 
might indicate that glycolysis was more stimulated dur- 
ing anoxia, than in ischaemia, where a relative inhibition 
of glycolysis gradually builts up. This progressive inhibi- 
tion of glycolysis during severe ischaemia has been 
proposed to result from lactate accumulation, which sup- 
posedly inhibits glyceraldehyde-3-phosphate dehydroge- 
nase, although the molecular mechanism of this inhibi- 
tion remains unknown [31]. 
The data presented indicate that the overall metabo- 
lism of glucose and glycogen was little affected by 
L-NAME both under normoxic and ischaemic condi- 
tions. However, in the presence of L-NAME, the concen- 
Table 3 
Effects of L-NAME, N-nitro+arginine and L-arginine on cyclic GMP 
content and coronary flow in the normoxic working rat heart 
cGMP Coronary flow 
(mnol/g d.w.) (ml/mm per g.d.w.) 
Controls 0.21 + 0.01 86& 9 
lo+ M L-NAME 0.17 * 0.01’ 6Of 5* 
10e6 M L-NoArg 0.16 f O.Ol* 65 + 5* 
1 mM L-Arg + L-NAME 0.22 f 0.01 85+ 5 
1 mM L-Arg 0.24 f 0.02 87f 10 
The hearts were perfused for 15 min in normoxic conditions with the 
indicated additions. The values are means k S.E.M. for at least 4 differ- 
ent preparations. L-NoArg, N-nitro-L-arginine; L-Arg, t-arginine. 
*P C 0.05 versus control. 
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tration of Fru-1,6-P, was decreased compared with the 
controls. This could result from a regulation of the pro- 
duction, or the disposal, of Fru-1,6-P, by either NO or 
cGMP. It is worth mentioning in this context that NO 
has been reported to inhibit in vitro glyceraldehyde3- 
phosphate dehydrogenase by auto-ADP-ribosylation of 
the enzyme [32,33]. One may speculate that this inhibi- 
tion could also occur under certain conditions in vivo. 
A moderate inhibition of PFK- 1 is not excluded because 
the concentration of hexose 6-phosphates increased 
slightly in the presence of L-NAME. 
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